作者
Elena V Rosca, Jacob E Koskimaki, Corban G Rivera, Niranjan B Pandey, Amir P Tamiz, Aleksander S Popel
发表日期
2011/8/1
来源
Current pharmaceutical biotechnology
卷号
12
期号
8
页码范围
1101-1116
出版商
Bentham Science Publishers
简介
Peptides have emerged as important therapeutics that are being rigorously tested in angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the discovery of endogenous proteins and protein fragments that inhibit microvessel formation (thrombospondin, endostatin) several peptides have shown promise in pre-clinical and clinical studies for cancer. Peptides have been derived from thrombospondin, collagens, chemokines, coagulation cascade proteins, growth factors, and other classes of proteins and target different receptors. Here we survey recent developments for anti-angiogenic peptides with length not exceeding 50 amino acid residues that have shown activity in pre-clinical models of cancer or have been tested in clinical trials; some of the peptides have been modified and optimized, e.g., through L-to-D and non-natural amino acid substitutions. We highlight technological …
学术搜索中的文章
EV Rosca, JE Koskimaki, CG Rivera, NB Pandey… - Current pharmaceutical biotechnology, 2011